GEO-CM01 Vaccine Description
The GEO-CM01 vaccine candidate from GeoVax is based upon a novel GV-MVA-VLP platform that integrates our recombinant Modified Vaccinia Ankara (MVA) vector technology with advanced antigen design and state-of-the-art manufacturing technologies.
On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. Vaccines produced on this platform are safe, highly immunogenic, suitable for repeated use, stable at refrigerator temperatures, can be lyophilized, and are amenable to rapid and affordable scale-up for use in both epidemic response and routine vaccination.
The production of VLPs (Virus Like Particles) in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.
The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus while providing the safety characteristics of a replication-defective vector.
GEO-CM01 Vaccine Indication
GEO-CM01 is a SARS-CoV-2 vaccine candidate that will be indicated to prevent COVID-19 disease in humans.
GEO-CM01 Vaccine Updates
- March 18, 2020 - GeoVax's Chief Scientific Officer Farshad Guirakhoo, Ph.D. stated, “We are pleased with the rapid progress with design, construction and in vitro characterizations of our three vaccine candidates. From here, we will narrow to one vaccine candidate based on the safety, immunogenicity and protective efficacy of our PreMaster Seed Viruses observed in upcoming animal studies. The final candidate will then proceed directly to manufacturing and initial human clinical testing for safety and immunogenicity.”
- March 4, 2020 - GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China. In late January, the Company entered into a letter of intent to begin a collaboration with BravoVax, a vaccine developer in Wuhan, China, to jointly develop a vaccine. Under the arrangement, upon receipt of vaccine candidates from GeoVax, BravoVax will provide testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities. Dr. Guirakhoo stated, “Development of a safe and effective vaccine to stem current and future epidemics of COVID-19 is a high priority for us. We have designed a number of vaccine candidates which will be narrowed through appropriate animal testing studies based on their safety, immunogenicity and protective efficacy. The final candidate will then be selected for manufacturing and initial human clinical testing for safety and immunogenicity. Our preliminary work with BravoVax is proceeding productively, with ongoing cross-contributions to the testing plans and respective dialogue with funding agencies.
- January 27, 2020 - GeoVax Labs, Inc. together with BravoVax, a vaccine developer in Wuhan, China, announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus. BravoVax will provide further development, including testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities.
GEO-CM01 Vaccine Dosage
GEO-CM01 Vaccine Clinical Trials